These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 23774700

  • 1. The effects of dipeptidyl-peptidase-IV inhibitor, vildagliptin, on the exocrine pancreas in spontaneously diabetic Goto-Kakizaki rats.
    Mizukami H, Inaba W, Takahashi K, Kamata K, Tsuboi K, Yagihashi S.
    Pancreas; 2013 Jul; 42(5):786-94. PubMed ID: 23774700
    [Abstract] [Full Text] [Related]

  • 2. Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats.
    Inaba W, Mizukami H, Kamata K, Takahashi K, Tsuboi K, Yagihashi S.
    Eur J Pharmacol; 2012 Sep 15; 691(1-3):297-306. PubMed ID: 22820107
    [Abstract] [Full Text] [Related]

  • 3. Vildagliptin selectively ameliorates GLP-1, GLUT4, SREBP-1c mRNA levels and stimulates β-cell proliferation resulting in improved glucose homeostasis in rats with streptozotocin-induced diabetes.
    Akarte AS, Srinivasan BP, Gandhi S.
    J Diabetes Complications; 2012 Sep 15; 26(4):266-74. PubMed ID: 22626875
    [Abstract] [Full Text] [Related]

  • 4. Studies in rodents with the dipeptidyl peptidase-4 inhibitor vildagliptin to evaluate possible drug-induced pancreatic histological changes that are predictive of pancreatitis and cancer development in man.
    Busch SJ, Hoffmann P, Sahota P, Johnson R, Kothny W, Meyer F, Foley JE.
    Diabetes Obes Metab; 2013 Jan 15; 15(1):72-6. PubMed ID: 22882290
    [Abstract] [Full Text] [Related]

  • 5. Relationships between the islets blood flow, nitric oxide, insulin, and cytosolic calcium in rat pancreatic islets: effects of DPP-IV inhibitor vildagliptin.
    Akarte AS, Srinivasan BP, Gandhi S.
    Eur J Pharm Sci; 2012 Apr 11; 45(5):546-51. PubMed ID: 22155545
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A novel long acting DPP-IV inhibitor PKF-275-055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic rats.
    Akarte AS, Srinivasan BP, Gandhi S.
    Biochem Pharmacol; 2012 Jan 15; 83(2):241-52. PubMed ID: 22015634
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. DPP4 inhibitor vildagliptin preserves β-cell mass through amelioration of endoplasmic reticulum stress in C/EBPB transgenic mice.
    Shimizu S, Hosooka T, Matsuda T, Asahara S, Koyanagi-Kimura M, Kanno A, Bartolome A, Etoh H, Fuchita M, Teruyama K, Takahashi H, Inoue H, Mieda Y, Hashimoto N, Seino S, Kido Y.
    J Mol Endocrinol; 2012 Oct 15; 49(2):125-35. PubMed ID: 22822047
    [Abstract] [Full Text] [Related]

  • 11. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans.
    Ahrén B, Schweizer A, Dejager S, Villhauer EB, Dunning BE, Foley JE.
    Diabetes Obes Metab; 2011 Sep 15; 13(9):775-83. PubMed ID: 21507182
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like Peptide 1 infusion increases liver glucose uptake in the conscious dog.
    Edgerton DS, Johnson KM, Neal DW, Scott M, Hobbs CH, Zhang X, Duttaroy A, Cherrington AD.
    Diabetes; 2009 Jan 15; 58(1):243-9. PubMed ID: 18840785
    [Abstract] [Full Text] [Related]

  • 13. Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats.
    Zhang Q, Xiao X, Li M, Yu M, Ping F, Zheng J, Wang T, Wang X.
    PLoS One; 2017 Jan 15; 12(10):e0184735. PubMed ID: 29036231
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats.
    Jin HY, Liu WJ, Park JH, Baek HS, Park TS.
    Arch Med Res; 2009 Oct 15; 40(7):536-44. PubMed ID: 20082866
    [Abstract] [Full Text] [Related]

  • 16. DPP4-inhibitor improves neuronal insulin receptor function, brain mitochondrial function and cognitive function in rats with insulin resistance induced by high-fat diet consumption.
    Pipatpiboon N, Pintana H, Pratchayasakul W, Chattipakorn N, Chattipakorn SC.
    Eur J Neurosci; 2013 Mar 15; 37(5):839-49. PubMed ID: 23240760
    [Abstract] [Full Text] [Related]

  • 17. Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner.
    Hausenloy DJ, Whittington HJ, Wynne AM, Begum SS, Theodorou L, Riksen N, Mocanu MM, Yellon DM.
    Cardiovasc Diabetol; 2013 Oct 22; 12():154. PubMed ID: 24148218
    [Abstract] [Full Text] [Related]

  • 18. Impact of the dipeptidyl peptidase-4 inhibitor vildagliptin on glucose tolerance and β-cell function and mass in insulin receptor substrate-2-knockout mice fed a high-fat diet.
    Sato K, Nakamura A, Shirakawa J, Muraoka T, Togashi Y, Shinoda K, Orime K, Kubota N, Kadowaki T, Terauchi Y.
    Endocrinology; 2012 Mar 22; 153(3):1093-102. PubMed ID: 22315446
    [Abstract] [Full Text] [Related]

  • 19. A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations.
    Fukuda-Tsuru S, Anabuki J, Abe Y, Yoshida K, Ishii S.
    Eur J Pharmacol; 2012 Dec 05; 696(1-3):194-202. PubMed ID: 23022337
    [Abstract] [Full Text] [Related]

  • 20. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.
    Ahrén B, Pacini G, Tura A, Foley JE, Schweizer A.
    Horm Metab Res; 2007 Nov 05; 39(11):826-9. PubMed ID: 17992639
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.